The release profile of a controlled release preparation of 5-aminosalicylic acid (Rowasa I®) in humans
- 1 January 1990
- journal article
- research article
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
- Vol. 33 (1) , 21-25
- https://doi.org/10.1007/bf02053196
Abstract
5-Aminosalicylic acid and its metabolite, N-ac-5-ASA, were measured in the plasma, urine, and ileostomy effluent of 24 ileostomates who ingested 750 mg Rowasa I® following an overnight fast. Twelve subjects previously had a small-bowel resection or had part of their small bowel out of circuit (mean 95 cm) (Group I) while 12 had an intact small bowel (Group II). The mean peak plasma concentration of N-ac-5-ASA was 1.11 μg/ml in Group 1 subjects compared with 2.80μg/ml in Group II subjects (P=N.S.). On average, 53.0 percent of the ingested Rowasa I was detected in the 24-hr ileostomy effluent of Group I subjects compared with 45.3 percent in the Group II subjects (P=N.S.). The mean recovery of 5-ASA and N-ac-5-ASA in urine was 8.5 percent in Group I and 35.6 percent in Group II subjects (PKeywords
This publication has 6 references indexed in Scilit:
- Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative ColitisNew England Journal of Medicine, 1987
- 5-Aminosalicylic Acid in the Treatment of Crohn's Disease: A 16-Week Double-Blind, Placebo-Controlled, Multicentre Study with Pentasa®Scandinavian Journal of Gastroenterology, 1986
- Pharmacotherapy of inflammatory bowel diseasePostgraduate Medicine, 1983
- Assay of 5-aminosalicylate and its acetylated metabolite in biological fluids by high-performance liquid chromatography on dynamically modified silicaJournal of Chromatography B: Biomedical Sciences and Applications, 1981
- AN EXPERIMENT TO DETERMINE THE ACTIVE THERAPEUTIC MOIETY OF SULPHASALAZINEThe Lancet, 1977
- SulfasalazineNew England Journal of Medicine, 1975